Analysts Set Expectations for PMN FY2026 Earnings

Promis Neurosciences (NASDAQ:PMN – Free Report) – Analysts at Brookline Capital Markets lifted their FY2026 earnings per share (EPS) estimates for Promis Neurosciences in a note issued to investors on Friday, November 13th. Brookline Capital Markets analyst F. Ahmed now expects that the company will earn ($4.93) per share for the year, up from their prior forecast of ($5.21). The consensus estimate for Promis Neurosciences’ current full-year earnings is ($4.46) per share. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q4 2026 earnings at ($1.47) EPS, Q1 2027 earnings at ($1.88) EPS, Q2 2027 earnings at ($1.46) EPS, Q3 2027 earnings at ($1.58) EPS and FY2027 earnings at ($6.69) EPS.

PMN has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating and set a $69.00 target price (up from $35.00) on shares of Promis Neurosciences in a research note on Tuesday, July 28th. Wall Street Zen raised Promis Neurosciences from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Weiss Ratings cut shares of Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Promis Neurosciences in a report on Thursday. Finally, Roth Capital cut their price target on shares of Promis Neurosciences to $15.00 and set a “buy” rating for the company in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Promis Neurosciences has an average rating of “Moderate Buy” and an average target price of $30.50.

View Our Latest Report on PMN

Promis Neurosciences Price Performance

PMN opened at $3.21 on Wednesday. The stock’s fifty day moving average is $8.37 and its 200-day moving average is $12.41. Promis Neurosciences has a one year low of $2.78 and a one year high of $27.40.

Promis Neurosciences (NASDAQ:PMN – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.39.

Hedge Funds Weigh In On Promis Neurosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Seven Fleet Capital Management LP purchased a new position in Promis Neurosciences in the 1st quarter worth about $135,000. ADAR1 Capital Management LLC acquired a new stake in Promis Neurosciences during the 1st quarter worth about $1,211,000. Yu Fan purchased a new stake in Promis Neurosciences during the first quarter valued at about $4,188,000. Ally Bridge Group NY LLC lifted its stake in Promis Neurosciences by 66.1% during the first quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after buying an additional 164,880 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Promis Neurosciences during the first quarter valued at about $16,418,000. Institutional investors and hedge funds own 50.13% of the company’s stock.

Insider Buying and Selling at Promis Neurosciences

In related news, Director Eugene Williams bought 26,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were acquired at an average cost of $3.43 per share, for a total transaction of $90,895.00. Following the acquisition, the director directly owned 40,213 shares of the company’s stock, valued at $137,930.59. The trade was a 193.25% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Neil Cashman bought 10,000 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were bought at an average cost of $3.86 per share, for a total transaction of $38,600.00. Following the completion of the transaction, the insider directly owned 14,532 shares of the company’s stock, valued at $56,093.52. This trade represents a 220.65% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 37,816 shares of company stock valued at $134,746. Corporate insiders own 1.50% of the company’s stock.

About Promis Neurosciences

(Get Free Report)

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing antibody-based treatments for neurodegenerative diseases. Its research focuses on misfolded proteins that may contribute to these conditions. The company’s technology is designed to identify disease-associated forms of proteins while distinguishing them from their normally functioning counterparts. Its lead program, PMN310, is an antibody candidate targeting toxic amyloid-beta oligomers for the potential treatment of Alzheimer’s disease.

Recommended Stories

Earnings History and Estimates for Promis Neurosciences (NASDAQ:PMN)

Receive News & Ratings for Promis Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Promis Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.